Investigational drug · Phase 2
Bemnifosbuvir
Also called: AT-527
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
17
Any phase or sponsor naming "Bemnifosbuvir"
First trial start
2023
May 30, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bemnifosbuvir", any sponsor or status.
- Phase 113
Conditions studied
As listed on its trial records.
- Chronic Hepatitis C Virus
- Hepatitis C, Chronic
- Hepatitis C
- Hepatic Cirrhosis
- HCV
Approved drugs for the same conditions: Hepatitis C · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Bemnifosbuvir" as an intervention, largest first.
- SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19Pivotal-lookingCompleted
Atea Pharmaceuticals, Inc.Industry
NCT05629962 · 2,285 participants · Start Nov 25, 2022 · Primary completion Apr 25, 2024
Drug: Bemnifosbuvir (BEM); Placebo · For: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection); COVID-19
Sites: Kingman, Arizona; Prescott, Arizona; Surprise, Arizona · 263 sites in all
- C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCVPivotal-lookingCompleted
Atea Pharmaceuticals, Inc.Industry
NCT06868264 · 940 participants · Start Apr 7, 2025 · Primary completion Jun 18, 2026
Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR); Sofosbuvir-Velpatasvir (SOF/VEL) · For: HEPATITIS C VIRUS CHRONIC INFECTION
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 105 sites in all
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCVPivotal-lookingActive, not recruiting
Atea Pharmaceuticals, Inc.Industry
NCT07037277 · 880 participants (planned) · Start Jun 2, 2025 · Primary completion Dec 2026
Drug: Bemnifosbuvir-Ruzasvir; Sofosbuvir-Velpatasvir · For: HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection and 1 more
Sites: Cairo, Egypt; Nice, France; Strasbourg, France · 107 sites in all
Atea Pharmaceuticals, Inc.Industry
NCT05904470 · 275 participants · Start May 30, 2023 · Primary completion Dec 9, 2024
Drug: Bemnifosbuvir; Ruzasvir · For: Chronic Hepatitis C Virus; Hepatitis C, Chronic; Hepatitis C and 2 more
Sites: San Antonio, Texas; Manaus, Brazil; Salvador, Brazil · 51 sites in all
- Study of AT-527 in Healthy Subjects Under Fasting Conditions or With a MealPivotal-lookingCompleted
Atea Pharmaceuticals, Inc.Industry
NCT05256732 · 136 participants · Start Feb 22, 2022 · Primary completion Aug 23, 2022
Drug: AT-527 fasted; AT-527 fed and 2 more · For: Healthy Volunteer Study
Sites: Québec, Canada
Atea Pharmaceuticals, Inc.Industry
NCT06204679 · 42 participants · Start Dec 14, 2023 · Primary completion Aug 25, 2024
Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions; Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions and 1 more · For: Healthy Volunteer Study
Sites: Cypress, California
Atea Pharmaceuticals, Inc.Industry
NCT05724693 · 39 participants · Start Jan 30, 2023 · Primary completion Apr 23, 2024
Drug: Bemnifosbuvir (BEM) · For: Healthy Volunteer; Hepatic Impairment
Sites: Orlando, Florida
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and RosuvastatinCompleted
Atea Pharmaceuticals, Inc.Industry
NCT06921941 · 38 participants · Start Apr 8, 2025 · Primary completion Jul 2, 2025
Drug: Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZR; Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR · For: Healthy Volunteer Study
Sites: Québec, Canada
Atea Pharmaceuticals, Inc.Industry
NCT05618314 · 36 participants · Start Oct 17, 2022 · Primary completion Jun 15, 2024
Drug: AT-527; AT-527 and 1 more · For: Healthy Volunteer; Renal Impairment
Sites: Québec, Canada
Atea Pharmaceuticals, Inc.Industry
NCT05905484 · 35 participants · Start Apr 25, 2023 · Primary completion May 31, 2023
Drug: Bemnifosbuvir (BEM); Placebo and 1 more · For: Healthy Volunteer Study
Sites: Québec, Canada
Newest research
PubMed records naming it or its code names, newest first.
- Tris(4-Halo-2,6-Difluorophenyl)Methyl Radicals Exhibiting Green Doublet Emission.
Ma X, Wang J, You J, et al. · Angew Chem Int Ed Engl 2026
- Coumarin 153 Fluorescent Probe for Highly Sensitive and Selective Detection of 2-Nitrodiphenylamine.
Wang T, Tang Y, Lei T, et al. · J Fluoresc 2026
- Class-selective and highly sensitive detection of β-diketone antibiotics in milk using a Eu(III)-anchored covalent organic framework probe via dual-mode ratiometric strategy.
Zhao Q, Wen SH, Yan G, et al. · Food Chem 2026
- Efficacy and safety of an 8-week bemnifosbuvir and ruzasvir regimen in chronic hepatitis C: Results from a Phase 2 study.
Jucov A, Conway B, Feld JJ, et al. · Hepatology 2026
- Multifunctional Additives With Dual Anions and Alkali Metal Cation for Efficient Perovskite Light-Emitting Diodes.
Han Q, Han P, Li X, et al. · Small 2026
- High-Birefringence Photoalignable Polymeric Films via In Situ Mesogenic Modification.
Kawatsuki N, Uemura K, Marui M, et al. · ACS Omega 2026
Also in development for Chronic Hepatitis C Virus
- RuzasvirAT-038Phase 21 trial
Atea Pharmaceuticals, Inc. · Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.